X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs STRIDES SHASUN LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA STRIDES SHASUN LTD CIPLA/
STRIDES SHASUN LTD
 
P/E (TTM) x 44.2 15.3 288.3% View Chart
P/BV x 3.9 1.8 217.1% View Chart
Dividend Yield % 0.3 0.6 59.7%  

Financials

 CIPLA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
STRIDES SHASUN LTD
Mar-17
CIPLA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs6221,275 48.8%   
Low Rs458918 49.9%   
Sales per share (Unadj.) Rs181.9389.6 46.7%  
Earnings per share (Unadj.) Rs12.928.0 46.0%  
Cash flow per share (Unadj.) Rs29.348.9 60.0%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.40.4 90.2%  
Book value per share (Unadj.) Rs155.7303.1 51.4%  
Shares outstanding (eoy) m804.5189.42 899.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.02.8 105.5%   
Avg P/E ratio x42.039.2 107.1%  
P/CF ratio (eoy) x18.422.4 82.2%  
Price / Book Value ratio x3.53.6 95.9%  
Dividend payout %15.516.1 96.6%   
Avg Mkt Cap Rs m434,51698,036 443.2%   
No. of employees `00023.05.8 397.3%   
Total wages/salary Rs m26,3385,881 447.8%   
Avg. sales/employee Rs Th6,349.16,005.9 105.7%   
Avg. wages/employee Rs Th1,143.01,014.0 112.7%   
Avg. net profit/employee Rs Th449.3431.2 104.2%   
INCOME DATA
Net Sales Rs m146,30234,834 420.0%  
Other income Rs m2,2871,686 135.7%   
Total revenues Rs m148,58936,520 406.9%   
Gross profit Rs m24,7586,428 385.2%  
Depreciation Rs m13,2291,872 706.9%   
Interest Rs m1,5942,269 70.2%   
Profit before tax Rs m12,2223,973 307.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-704 -1,941.7%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m1,798470 382.5%   
Profit after tax Rs m10,3542,501 414.0%  
Gross profit margin %16.918.5 91.7%  
Effective tax rate %14.711.8 124.3%   
Net profit margin %7.17.2 98.6%  
BALANCE SHEET DATA
Current assets Rs m87,37038,165 228.9%   
Current liabilities Rs m33,08130,402 108.8%   
Net working cap to sales %37.122.3 166.5%  
Current ratio x2.61.3 210.4%  
Inventory Days Days8777 112.4%  
Debtors Days Days62104 59.6%  
Net fixed assets Rs m111,56737,639 296.4%   
Share capital Rs m1,609894 179.9%   
"Free" reserves Rs m123,64526,210 471.7%   
Net worth Rs m125,25427,105 462.1%   
Long term debt Rs m36,45416,377 222.6%   
Total assets Rs m209,53281,168 258.1%  
Interest coverage x8.72.8 315.1%   
Debt to equity ratio x0.30.6 48.2%  
Sales to assets ratio x0.70.4 162.7%   
Return on assets %5.75.9 97.0%  
Return on equity %8.39.2 89.6%  
Return on capital %8.512.1 70.5%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06613,465 379.2%   
Fx outflow Rs m17,6784,076 433.7%   
Net fx Rs m33,3889,389 355.6%   
CASH FLOW
From Operations Rs m23,8242,881 826.8%  
From Investments Rs m-13,127-7,051 186.2%  
From Financial Activity Rs m-13,2393,382 -391.4%  
Net Cashflow Rs m-2,478-788 314.6%  

Share Holding

Indian Promoters % 16.0 27.7 57.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 37.8 32.3%  
FIIs % 23.7 8.6 275.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 25.9 101.2%  
Shareholders   161,166 56,241 286.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  SANOFI INDIA  NATCO PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 16, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS